Insect Cell Lines Market size is poised to reach USD 5 Billion by the end of 2036, growing at a CAGR of 12% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of insect cell lines was USD 1.2 Billion. The reason behind the growth is due to the increasing production of vaccines. Several veterinary and human vaccines are commercially produced using the baculovirus-insect cell expression method that are desirable for high-level eukaryotic protein synthesis. There are already around 1 billion doses of vaccine produced each month by producers globally, and this number will increase to over 10 billion by the end of 2021, and, overall vaccine production reach over 22 billion by June 2022.
The rising need for insect-derived products is believed to fuel the insect cell lines market. Insects have recently been suggested as one of the most viable alternatives to animal protein which has led to the production of health-related products by insect cell lines using vectors created from insect viruses in insect cells, which give high levels of protein expression.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~12% |
|
Base Year Market Size (2023) |
~ USD 1.2 Billion |
|
Forecast Year Market Size (2036) |
~ USD 5 Billion |
|
Regional Scope |
|
Product Type (Sf9, Sf21, High Five, S2)
The high-five segment in the insect cell lines market is estimated to gain a robust revenue share of 40% in the coming years impelled by the rising prevalence of autoimmune disorders. For instance, more than 3% of the world's population suffers from at least one autoimmune illness. It is expected that air pollution, infections, personal lifestyles, stress, and climate change are likely contributing factors to the sharp rise in autoimmune illnesses that are occurring in many regions of the world. The examination of autoimmune-mediated responses has benefited greatly from the use of recombinant proteins that are employed in the creation of biotherapeutic medications. These factors are expected to drive the demand for high-five insect cell lines.
An insect cell line called High Five (BTI-Tn-5B1-4) was developed from the ovarian cells of the cabbage looper which have been extensively studied for the synthesis of heterologous proteins. Moreover, the High Five cell line, the BTI-Tn5B1-4 insect cell line encourages the production of larger concentrations of recombinant proteins that are proteins encoded by recombinant DNA that are created through the introduction of particular genes into hosts, such as bacteria or yeast. According to current estimates, the global prevalence of autoimmune illnesses is increasing by over 7% yearly.
Besides this, the Sf9 segment in the insect cell lines market is poised to gain a significant revenue share. Sf9 insect cell lines is a clonal strain obtained from the parental Spodoptera frugiperda cell line IPLB-Sf-21-AE, and it is frequently employed in insect cell culture for the manufacture of recombinant proteins.
Application (Biopharmaceutical Manufacturing, Tissue Culture & Engineering, Gene Therapy, Cytogenetic)
Insect cell lines market from biopharmaceutical manufacturing segment is set to garner a notable share shortly. Biopharmaceuticals, or medications derived from live organisms or their cells, are highly effective in treating a variety of ailments and are manufactured by biosynthesis generally that produce proteins and nucleic acids. Moreover, recombinant DNA technology is used to create biopharmaceuticals, which use a host cell to express and secrete therapeutic proteins that can be utilized as medicines, vaccines, and diagnostic tools.
Insect cells can effectively express recombinant proteins and are typically employed for the creation of virus-like particles and vaccines have been widely employed in recent years to produce many kinds of physiologically active recombinant proteins as a cell line retains favorable growth and productivity characteristics.
End-User (Pharmaceuticals, Research Laboratories, Pathology Labs)
The pharmaceuticals manufacturing segment in the insect cell lines market is anticipated to garner a notable share during the forecast timeframe. Pharmaceutical manufacturing is the process of creating pharmaceutical medications on an industrial scale and includes physical procedures such as blending, compression, filtration, heating, encapsulating, shearing, coating, and drying.
The most often utilized insect cell lines are High Five, Sf9, and S2 are often used for the production of vaccines and other biologicals and provide several technological benefits over mammalian cells. Moreover, it has previously been suggested that the preferred biosecurity technique for vaccine manufacture, especially for upcoming influenza pandemic vaccines, is the insect cell expression system as they are capable of carrying out many of the post-translational modifications that viral antigens frequently need.
Our in-depth analysis of the global insect cell lines market includes the following segments:
|
Product Type |
|
|
Application |
|
|
End-User |
|
North American Market Forecast
The insect cell lines market in North America is predicted to account for the largest share of 35% by 2036 impelled by increasing spending in the production of vaccines. This, as a result, may lead to increasing development of vaccines in the region which is expected to drive the demand for insect cell lines. For instance, as of 2020, American biopharmaceutical companies worked on over 250 vaccines to prevent and treat diseases including cancer, and other autoimmune disorders.
The US government spent over USD 31 billion on the research, development, and acquisition of mRNA COVID-19 vaccines, with significant sums spent in the three decades before the pandemic and through March 2022.
European Market Statistics
The Europe insect cell lines market is estimated to be the second largest, during the forecast period led by rising spending in research & development in the healthcare industry. This has led to an increase in focus on research and development in the area of creative medicines by the pharmaceutical industry in the region which is essential if diseases and disorders are to be treated efficiently. In Europe, the research-based pharmaceutical business alone spent around €37 billion on R&D in 2019 and over €35 billion in 2020.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?